PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1517645
PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1517645
Montelukast Sodium Market - By Product Type (Montelukast Sodium Amorphous, Montelukast Sodium Crystalline) Dosage Form (Tablets, Oral Solutions), Application (Asthma, Allergic Rhinitis, Urticaria), Distribution Channel - Global Forecast (2024 - 2032)
Montelukast sodium market size is estimated to register 11.4% CAGR between 2024 and 2032, backed by the rising prevalence of respiratory diseases, such as asthma and allergic rhinitis worldwide. As per the National Institute of Health, around 400 million people globally are affected with allergic rhinitis worldwide.
Increased pollution and changing lifestyles are leading to the increased use of respiratory medications to improve symptoms. Moreover, researchers are uncovering new uses for drugs in treating respiratory diseases likes COPD and bronchitis, leading to increased product demand. Collaborations between pharmaceutical companies and research institutes are also driving the market growth.
The montelukast sodium industry is segmented into product type, dosage form, application, distribution channel and region.
With respect to dosage form, the market size from the oral solutions segment is anticipated to witness substantial growth through 2032, owing to their convenience, ease of administration, and enhanced patient compliance. Patient-centered healthcare is emphasizing oral solutions as an alternative to tablets or granules, particularly for children and the elderly for offering precise dose control for those who have difficulty swallowing. Oral solutions also provide better taste as well as increased patient acceptance and compliance in healthcare settings.
Montelukast sodium industry from the allergic rhinitis application segment will generate notable revenue during 2024-2032, backed by the efficiency of drugs in managing symptoms related to respiratory conditions. Allergic rhinitis is a common condition causing symptoms like nasal congestion, sneezing, and itchy eyes. To that end, montelukast sodium is used as it targets leukotrienes to relieve symptoms and improve respiratory health for sufferers.
Asia Pacific montelukast sodium industry is slated to witness a significant growth rate through 2032, attributed to the rising prevalence of respiratory diseases due to environmental pollution, changing lifestyles, and genetic predispositions. Urban growth and industrial expansion in Asia are deteriorating air quality. The growing government support for improving health infrastructure and expanding access to medication will also stimulate the regional market growth.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360-degree synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increasing prevalence of respiratory diseases
- 3.2.1.2 Advancements in drug delivery
- 3.2.1.3 Growing awareness and diagnosis
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 Side effects and safety concerns
- 3.2.2.2 Alternative treatment options
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Porter's analysis
- 3.6 Pestel analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Competitive positioning matrix
- 4.4 Strategy outlook matrix
Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Montelukast sodium amorphous
- 5.3 Montelukast sodium crystalline
Chapter 6 Market Estimates and Forecast, By Dosage Form, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Tablets
- 6.3 Oral solutions
Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Asthma
- 7.3 Allergic rhinitis
- 7.4 Urticaria
- 7.5 Other applications
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 Hospital pharmacies
- 8.3 Retail pharmacies
- 8.4 Online pharmacies
Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 9.1 Key trends
- 9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
- 9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
- 9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
- 9.6 Middle East And Africa
- 9.6.1 Saudi Arabia
- 9.6.2 South Africa
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
- 10.1 Apotex Inc.
- 10.2 Cipla Limited
- 10.3 Dr. Reddy's Laboratories Ltd.
- 10.4 Intas Pharmaceuticals Ltd
- 10.5 Merck & Co., Inc.
- 10.6 Morepen Laboratories Limited
- 10.7 Mylan N.V.
- 10.8 Sandoz AG
- 10.9 Sanofi
- 10.10 Sun Pharma Industries Limited.
- 10.11 Teva Pharmaceutical Industries Limited
